About 40% of Americans will develop a form of cancer at some point in their lifetime, according to the American Cancer ...

Lung cancer is the leading cause of cancer-related deaths, and the most common form is a non-small-cell type called adenocarcinoma.

Patients with vs without rheumatoid arthritis (RA), especially those with RA-associated interstitial lung disease (RA-ILD), have a significantly higher risk of developing lung cancer, according to ...

Data showed that treatment with Annamycin resulted in statistically-significant inhibition of tumor growth and extension of survival in orthotopic lung cancer models, Moleculin Biotech said, which is ...

(RTTNews) - Black Diamond Therapeutics, Inc. (BDTX) announced positive initial Phase 2 results for BDTX-1535 in patients with relapsed or refractory non-small cell lung cancer also known as NSCLC, ...

AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically ...

Lung cancer is one of the most common and aggressive cancers. Its most characteristic symptoms include coughing, shortness of ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

Here in North Carolina, breast cancer is the most commonly diagnosed cancer — at more than double the rate of lung cancer, the next most common cancer. Across the U.S., 272,454 new female breast ...

Another Phase 3 trial failed to improve on the current standard of care for lung cancer patients. AstraZeneca's American ...

Lung cancer is one of the most common and aggressive cancers. Its most characteristic symptoms include coughing, shortness of ...

AstraZeneca's cancer drug, datopotamab deruxtecan, failed to meet targets in a Phase 3 trial, clouding the possibility of approval from the U.S. Food and Drug Administration. Shares were down 1.2% at ...